Published in Vaccine Weekly, September 13th, 2006
The paper, titled "Immunogenicity and Tolerance of Ascending Doses of a Recombinant Protective Antigen (rPA102) Anthrax Vaccine: A Randomized, Double-blinded, Controlled, Multicenter Trial," presents data which demonstrated a clear relationship between the rPA102 dose administered and the subsequent immune response. All injections were administered 4 weeks apart and at each dose level examined, three injections of the vaccine candidate yielded higher antibody titers than with two...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.